MAGED2 mRNA was considerably greater in low-grade glioma (p < 0.001) and high-grade glioma (p < 0.001) than in normal brain tissues, but there was no significant difference in MAGED2 mRNA between high-grade and low-grade gliomas (Figure 2A). This evidence concerns the gene MAGED2 and central nervous system cancer.